Haloperidol Richter

Haloperidol Richter is an injectable solution containing the active ingredient haloperidol, a butyrophenone antipsychotic. It is supplied in a sterile intramuscular formulation and is marketed in the European Union as a prescription‑only product. Haloperidol works as a dopamine D2 receptor antagonist and is used under medical supervision for several psychiatric conditions. The preparation does not contain a listed strength, reflecting standard dosing concentrations for clinical use.

Haloperidol Richter is indicated for several psychiatric disorders where dopamine blockade is therapeutic.

- Management of schizophrenia symptoms, including reduction of hallucinations, delusions, and thought disorder. - Treatment of acute psychotic episodes in emergency settings, providing rapid intramuscular control of agitation. - Control of manic episodes associated with bipolar disorder, helping to stabilize mood and decrease risky behavior. - Reduction of motor and vocal tics in Tourette syndrome, improving functional ability and quality of life. - Adjunct therapy for severe agitation when oral medications are not feasible, allowing prompt intramuscular administration. - Management of severe behavioral disturbances in institutional settings when rapid pharmacologic control is required for safety.

Haloperidol Richter may cause a range of adverse effects that vary in frequency and severity.

Common: - Drowsiness or sedation, often noticeable within hours after injection. - Extrapyramidal symptoms such as mild tremor, rigidity, or restlessness. - Dry mouth and decreased salivation. - Constipation or reduced gastrointestinal motility. - Blurred vision or transient visual disturbances.

Serious: - Neuroleptic malignant syndrome, a rare but life‑threatening reaction with fever and muscle rigidity. - Torsades de pointes or other significant cardiac arrhythmias, especially in patients with pre‑existing QT prolongation.

Clinicians should consider several precautions when prescribing Haloperidol Richter to ensure patient safety and optimal outcomes.

- Assess cardiac history and baseline ECG, as haloperidol can prolong the QT interval. - Evaluate for a history of neuroleptic malignant syndrome or severe extrapyramidal reactions. - Use the lowest effective dose, especially in elderly patients or those with hepatic impairment. - Monitor for signs of worsening depression or emergence of suicidal thoughts during treatment. - Avoid use during pregnancy unless benefits clearly outweigh potential risks, due to limited safety data.

Haloperidol Richter can interact with other medications, altering its efficacy or increasing the risk of adverse events.

Avoid: - Concomitant use with other strong dopamine antagonists or high‑potency antipsychotics, which may intensify extrapyramidal effects. - Combination with medications that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution: - Co‑administration with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase haloperidol plasma levels. - Use alongside CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce therapeutic effectiveness. - Caution when given with central nervous system depressants (e.g., benzodiazepines, opioids) due to additive sedation.